RxDoctor Payments DataLook up a doctor →

Jyotir Mehta, MD

Critical Care Medicine · Albany, GANPI 1306830203

Payments from drug & device makers

$11,541in general payments, 2019–2025

Across 413 payments — averaging $27.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • GSK$2K
  • Covidien LP$1K
  • Insmed, Inc.$650
  • Johnson & Johnson$544
  • Boehringer Ingelheim$524
  • plus $4K from 42 others

What the payments were for

  • Travel & lodging$1,19010%
  • Food & beverage$7,59466%
  • Education$2,75724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,541 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.

See all critical care medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$75,809
Medicare patients
449
Services billed
1,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan65$830,409
OfevNintedanib Esylate53$683,563
UptraviSelexipag13$287,958
AdempasRiociguat17$233,929
Trelegy ElliptaFluticasone/Umeclidin/Vilanter268$195,177
Dupixent PenDupilumab15$56,293
TezspireTezepelumab-Ekko12$52,652
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$43,030
Orenitram ErTreprostinil Diolamine12$40,749
Spiriva RespimatTiotropium Bromide77$40,487
SymbicortBudesonide/Formoterol Fumarate142$36,373
Tadalafil46$31,683
Breo ElliptaFluticasone/Vilanterol59$24,285
Bosentan11$15,361
Combivent RespimatIpratropium/Albuterol Sulfate22$10,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan$389$1,133,72789 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$524$740,348164 claims
BayerAdempas$128$233,92917 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,909$227,478346 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$478$132,056224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.

Other critical care medicine in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →